The discipline of pharmacology can be divided into many sub disciplines each with a specific focus.

Systems of the body[



A variety of topics

involved with pharmacology, including <u>neuropharmacology</u>, renal pharmacology, human <u>metabolism</u>, intracellular metabolism, and intracellular regulation.

Pharmacology can also focus on specific <u>systems</u> comprising the body. Divisions related to bodily systems study the effects of drugs in different systems of the body. These include <u>neuropharmacology</u>, in the <u>central</u> and <u>peripheral nervous systems</u>; <u>immunopharmacology</u> in the immune system. Other divisions

include <u>cardiovascular</u>, <u>renal</u> and <u>endocrine</u> pharmacology. <u>Psychopharm</u> <u>acology</u> is the study of the use of drugs that affect the <u>psyche</u>, mind and behavior (e.g. antidepressants) in treating mental disorders (e.g. depression).<sup>[15][16]</sup> It incorporates approaches and techniques from neuropharmacology, animal behavior and behavioral neuroscience, and is interested in the behavioral and neurobiological mechanisms of action of psychoactive drugs.<sup>[citation needed]</sup> The related field of <u>neuropsychopharmacology</u> focuses on the effects of drugs at the overlap between the nervous system and the psyche.

<u>Pharmacometabolomics</u>, also known as pharmacometabonomics, is a field which stems from <u>metabolomics</u>, the quantification and analysis of <u>metabolites</u> produced by the body.<sup>[17][18]</sup> It refers to the direct measurement of <u>metabolites</u> in an individual's bodily fluids, in order to predict or evaluate the <u>metabolism</u> of <u>pharmaceutical</u> compounds, and to better understand the pharmacokinetic profile of a drug.<sup>[17][18]</sup> Pharmacometabolomics can be applied to measure <u>metabolite</u> levels following the administration of a drug, in order to monitor the effects of the drug on metabolic

pathways. <u>Pharmacomicrobiomics</u> studies the effect of microbiome variations on drug disposition, action, and

toxicity.<sup>[19]</sup> Pharmacomicrobiomics is concerned with the interaction between drugs and the gut <u>microbiome</u>. <u>Pharmacogenomics</u> is the application of genomic technologies to <u>drug discovery</u> and further characterization of drugs related to an organism's entire genome.<sup>[citation</sup> <u>needed]</u> For pharmacology regarding individual

genes, <u>pharmacogenetics</u> studies how genetic variation gives rise to differing responses to drugs.<sup>[citation needed]</sup> <u>Pharmacoepigenetics</u> studies the underlying <u>epigenetic</u> marking patterns that lead to variation in an individual's response to medical treatment.<sup>[20]</sup>

Clinical practice and drug discovery[ Main articles: <u>Drug development</u> and <u>Drug Discovery Hit to Lead</u>

A toxicologist working in a lab.

Pharmacology can be applied within clinical sciences. <u>Clinical</u> <u>pharmacology</u> is the application of pharmacological methods and principles in the study of drugs in humans.<sup>[21]</sup> An example of this is posology, which is the study of how medicines are dosed.<sup>[22]</sup>

Pharmacology is closely related to <u>toxicology</u>. Both pharmacology and toxicology are scientific disciplines that focus on understanding the properties and actions of chemicals.<sup>[23]</sup> However, pharmacology emphasizes the therapeutic effects of chemicals, usually drugs or compounds that could become drugs, whereas toxicology is the study of chemical's adverse effects and risk assessment.<sup>[23]</sup>

Pharmacological knowledge is used to advise <u>pharmacotherapy</u> in <u>medicine</u> and <u>pharmacy</u>.

## Drug discovery[

<u>Drug discovery</u> is the field of study concerned with creating new drugs. It encompasses the subfields of <u>drug design</u> and <u>development</u>.<sup>[24]</sup> Drug discovery starts with drug design, which is the <u>inventive</u> process of finding new drugs.<sup>[25]</sup> In the most basic sense, this involves the design of molecules that are complementary in <u>shape</u> and <u>charge</u> to a given biomolecular target.<sup>[26]</sup> After a <u>lead compound</u> has been identified through drug discovery, drug development involves bringing the drug to the market.<sup>[24]</sup> Drug discovery is related to <u>pharmacoeconomics</u>, which is the sub-discipline of <u>health economics</u> that considers the value of drugs<sup>[27][28]</sup> Pharmacoeconomics evaluates the cost and benefits of drugs in order to guide optimal healthcare resource allocation.<sup>[29]</sup> The techniques used for the <u>discovery</u>, formulation, manufacturing and quality control of drugs discovery is studied by <u>pharmaceutical engineering</u>, a branch of <u>engineering</u>.<sup>[30]</sup> <u>Safety pharmacology</u> specialises in detecting and investigating potential undesirable effects of drugs.<sup>[31]</sup>



The drug discovery cycle.

<u>Development of medication</u> is a vital concern to <u>medicine</u>, but also has strong <u>economical</u> and <u>political</u> implications. To protect the <u>consumer</u> and prevent abuse, many governments regulate the manufacture, sale, and administration of medication. In the <u>United States</u>, the main body that regulates pharmaceuticals is the <u>Food and Drug</u> <u>Administration</u>; they enforce <u>standards</u> set by the <u>United States</u> <u>Pharmacopoeia</u>. In the <u>European Union</u>, the main body that regulates pharmaceuticals is the <u>EMA</u>, and they enforce standards set by the <u>European Pharmacopoeia</u>.

The metabolic stability and the reactivity of a library of candidate drug compounds have to be assessed for drug metabolism and toxicological studies. Many methods have been proposed for quantitative predictions in drug metabolism; one example of a recent computational method is SPORCalc.<sup>[32]</sup> A slight alteration to the chemical structure of a medicinal compound could alter its medicinal properties, depending on how the alteration relates to the structure of the substrate or receptor site on which it acts: this is called the structural activity relationship (SAR). When a useful activity has been identified, chemists will make many similar compounds called analogues, to try to maximize the desired medicinal effect(s). This can take anywhere from a few years to a decade or more, and is very expensive.<sup>[33]</sup> One must also determine how safe the medicine is to consume, its stability in the human body and the best form for delivery to the desired organ system, such as tablet or aerosol. After extensive testing, which can take up to six years, the new medicine is ready for marketing and selling.<sup>[33]</sup>

Because of these long timescales, and because out of every 5000 potential new medicines typically only one will ever reach the open market, this is an expensive way of doing things, often costing over 1 billion dollars. To recoup this outlay pharmaceutical companies may do a number of things:<sup>[33]</sup>

- Carefully research the demand for their potential new product before spending an outlay of company funds.<sup>[33]</sup>
- Obtain a patent on the new medicine preventing other companies from producing that medicine for a certain allocation of time.<sup>[33]</sup>

The <u>inverse benefit law</u> describes the relationship between a drugs therapeutic benefits and its marketing.

When designing drugs, the <u>placebo</u> effect must be considered to assess the drug's true therapeutic value.

Drug development uses techniques from <u>medicinal chemistry</u> to chemically design drugs. This overlaps with the biological approach of finding targets and physiological effects.